Association of cystatin C with adverse outcomes

Current Opinion in Nephrology and Hypertension

Volumn 18, Issue 3, 2009, Pages 258-263

  Madero, Magdalena ^a   Sarnak, Mark J ^b  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; Cystatin C, kidney disease; Mortality

Indexed keywords

ALBUMIN; CREATININE; CYSTATIN C;

AGING; ARTERY DISEASE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COGNITIVE DEFECT; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MORTALITY; MUSCULOSKELETAL DISEASE; NONHUMAN; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK FACTOR; STROKE; ANIMAL; CHRONIC KIDNEY FAILURE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; CYSTATIN C; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; RISK FACTORS;

EID: 67049107987     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328326f3dd     Document Type: Review

References (45)

1. Köttgen A, Selvin E, Stevens LA, et al. Serum cystatin C in the United States: The Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2008; 51:385-394. This analysis from the Third National Health and Nutrition Examination Survey (NHANES III) evaluates the determinants of cystatin C across a wide age range and different ethnicities. Serum cystatin C level was related to sex and ethnicity, even in young healthy individuals. The prevalence of increased cystatin C levels increased dramatically with age, reaching greater than 50% after the age of 80 years in both sexes and all ethnic groups.
2. 2), serum cystatin C level alone provided GFR estimates that were nearly as accurate as serum creatinine level adjusted for age, sex, and race. An equation including serum cystatin C level in combination with serum creatinine level, age, sex, and race provided the most accurate estimate of GFR.
3. Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65:1416-1421.
4. Manetti L, Pardini E, Genovesi M, et al. Thyroid function differently affects serum cystatin C and creatinine concentrations. J Endocrinol Invest 2005; 28:346-349.
5. Risch L, Herklotz R, Blumberg A, et al. Effects of glucocorticoid immuno-suppression on serum cystatin C concentrations in renal transplant patients. Clin Chem 2001; 47:2055-2059.
6. Muntner P, Winston J, Uribarri J, et al. Overweight, obesity, and elevated serum cystatin C levels in adults in the United States. Am J Med 2008; 121:341-348.
7. Retnakaran R, Connelly PW, Harris SB, et al. Cystatin C is associated with cardiovascular risk factors and metabolic syndrome in Aboriginal youth. Pediatr Nephrol 2007; 22:1007-1013.
8. Taleb S, Cancello R, Clement K, et al. Cathepsin s promotes human preadipocyte differentiation: possible involvement of fibronectin degradation. Endocrinology 2006; 147:4950-4959.
9. Young JA, Hwang S, Sarnak M, et al. Association of visceral and subcutaneous adiposity with kidney function. Clin J Am Soc Nephrol 2008; 3:1786-1791.
10. Menon V, Shlipak M, Wang X, et al. Cystatin C as a risk factor for outcomes in CKD. Ann Intern Med 2007; 147:19-27. This study using data from the Modification in Diet in Renal Disease (MDRD) Study compared cystatin C, serum creatinine, estimated glomerular filtration rate (GFR) and measured GFR as risk factors for death and kidney failure in chronic kidney disease (CKD). The association of cystatin C level with all cause and CVD mortality was perhaps stronger than that of iothalamate GFR.
11. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40:221-226.
12. Premaratne E, MacIsaac RJ, Finch S, et al. Serial measurements of cystatin C are more accurate than creatinine-based methods in detecting declining renal function in type 1 diabetes. Diabetes Care 2008; 5:971-973.
13. Perkins BA, Nelson RG, Ostrander BE, et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 2005; 16:1404-1412.
14. Shlipak MG. Cystatin C research priorities targeted to clinical decision making. Am J Kidney Dis 2008; 51:358-361.
15. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352: 2049-2060.
16. Shlipak MG, Wassel Fyr CL, Chertow GM, et al. Cystatin C and mortality risk in the elderly: The Health, Aging, and Body Composition Study. J Am Soc Nephrol 2006; 17:254-261.
17. Kestenbaum B, Rudser K, de Boer I, et al. Differences in kidney function and incident hypertension: The Multi-Ethnic Study of Atherosclerosis. Ann Intern Med 2008; 148:501-508. Using data from the Multi-Ethnic Study of Atherosclerosis (MESA), the authors examined the association between cystatin C and incident hypertension amongst 2767 participants without prevalent hypertension. Cystatin C was associated with incident hypertension among individuals without clinical kidney or cardiovascular disease.
18. Donahue RP, Stranges S, Rejman K, et al. Elevated cystatin Cconcentration and progression to prediabetes: the Western New York study. Diabetes Care 2007; 7:1724-1729.
19. Sarnak MJ, Katz R, Stehman-Breen CO, et al. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med 2005; 142:497-505.
20. Shlipak MG, Katz R, Fried LF, et al. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol 2005; 45:268-271.
21. Moran A, Katz R, Smith NL, Fried LF, et al. Cystatin C concentration as a predictor of systolic and diastolic heart failure. J Card Fail 2008; 14:19-26.
22. Djoussé L, Kurth T, Gaziano JM. Cystatin C and risk of heart failure in the Physicians' Health Study (PHS). Am Heart J 2008; 155:82-86.
23. Jernberg T, Lindahl B, James S, et al. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004; 110:2342-2348.
24. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 2005; 51:321-327.
25. Zethelius B, Berglund L, Sundström J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358:2107-2116. In this study that included 1135 patients from the Uppsala Longitudinal Study of Adult Men (ULSAM), the simultaneous addition of several biomarkers of cardiovascular and kidney abnormalities including cystatin C substantially improved prediction of CVD death beyond that of a model based only on established risk factors.
26. Ni L, Lu J, Hou LB, et al. Cystatin C, associated with hemorrhagic and ischemic stroke, is a strong predictor of the risk of cardiovascular events and death in Chinese. Stroke 2007; 38:3287-3288.
27. Seliger SL, Longstreth WT Jr, Katz R, et al. Cystatin C and subclinical brain infarction. J Am Soc Nephrol 2005; 16:3721-3727.
28. O'Hare AM, Newman AB, Katz R, et al. Cystatin C and incident peripheral arterial disease events in the elderly: results from the Cardiovascular Health Study. Arch Intern Med 2005; 165:2666-2670.
29. Arpegård J, Ostergren J, de Faire U, et al. Cystatin C: a marker of peripheral atherosclerotic disease? Atherosclerosis 2008; 199:397-401.
30. Albert MA, Rifai N, Ridker PM. Plasma levels of cystatin-C and mannose binding protein are not associated with risk of developing systemic atherosclerosis. Vasc Med 2001; 6:145-149.
31. Sarnak M, Katz R, Fried L, et al. Cystatin C and aging success. Arch Intern Med 2008; 168:147-153. This study evaluated the association of cystatin C with successful aging in a cohort of 2140 patients from the Cardiovascular Health Study. Cystatin C, even within the range of relatively normal kidney function, was associated with a reduction in successful life years.
32. Fried LF, Katz R, Sarnak MJ, et al. Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol 2005; 16:3728-3735.
33. Ensrud KE, Lui LY, Taylor BC, et al. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 2007; 167:133-139.
34. Fried LF, Biggs ML, Shlipak MG, et al. Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol 2007; 18:282-286.
35. Fried LF, Shlipak MG, Stehman-Breen C, et al. Kidney function predicts the rate of bone loss in older individuals: the Cardiovascular Health Study. J Gerontol A Biol Sci Med Sci 2006; 61:743-748.
36. Odden MC, Chertow GM, Fried LF, et al. Cystatin C and measures of physical function in elderly adults: the Health, Aging, and Body Composition (HABC) Study. Am J Epidemiol 2006; 164:1180-1189.
37. McManus D, Shlipak M, Ix JH, et al. Association of cystatin C with poor exercise capacity and heart rate recovery: data from the heart and soul study. Am J Kidney Dis 2007; 49:365-372.
38. Fried LF, Lee JS, Shlipak M, et al. Chronic kidney disease and functional limitation in older people: Health, Aging and Body Composition study. J Am Geriat Soc 2006; 54:750-756.
39. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997; 278:1363-1371.
40. Yaffe K, Lindquist K, Shlipak MG, et al. Cystatin C as a marker of cognitive function in elders: findings from the health ABC study. Ann Neurol 2008; 63:798-802.
41. Sundelöf J, Arnlöv J, Ingelsson E, et al. Serum cystatin C and the risk of Alzheimer disease in elderly men. Neurology 2008; 71:1072-1079.
42. Kaeser SA, Herzig MC, Coomaraswamy J, et al. Cystatin C modulates cerebral beta-amyloidosis. Nat Genet 2007; 39:1437-1439.
43. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33:278-285.
44. 2 per year) had increased mortality risk, independent of baseline eGFR and other demographic variables.
45. Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145:237-246.